OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
Sophie Warren, Myrto Barmpouni, Vasiliki Kossyvaki, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1369-1369
Open Access | Times Cited: 15

Showing 15 citing articles:

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis
An Ta, Felicitas Kühne, Maren Laurenz, et al.
Infectious Diseases and Therapy (2024) Vol. 13, Iss. 6, pp. 1333-1358
Open Access | Times Cited: 8

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants
Mark H. Rozenbaum, Liping Huang, Johnna Perdrizet, et al.
Vaccine (2024) Vol. 42, Iss. 3, pp. 573-582
Open Access | Times Cited: 7

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan
Masayoshi Shinjoh, Kanae Togo, Tomoyuki Hayamizu, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 485-497
Open Access | Times Cited: 5

Cost-effectiveness analysis of the pediatric 20-valent pneumococcal conjugate vaccine compared with lower-valent alternatives in Argentina
Lucila Rey‐Ares, An Ta, D. Freigofaite, et al.
Vaccine (2024) Vol. 42, Iss. 23, pp. 126043-126043
Open Access | Times Cited: 4

An economic evaluation of pneumococcal conjugate vaccines, PCV20 versus PCV15, for the prevention of pneumococcal disease in the Swedish pediatric population
Ann-Charlotte Fridh, Andreas Palmborg, An Ta, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3

Cost-Effectiveness Analysis of Pneumococcal Vaccines in the Pediatric Population: A Systematic Review
Nam Xuan Vo, Huong Pham, Uyen My Bui, et al.
Healthcare (2024) Vol. 12, Iss. 19, pp. 1950-1950
Open Access | Times Cited: 2

Pediatric Otitis Media in the New Pneumococcal Conjugate Vaccines Era: What’s Next?
Tal Marom, Sharon Ovnat Tamir
The Pediatric Infectious Disease Journal (2024) Vol. 43, Iss. 6, pp. 604-605
Closed Access | Times Cited: 1

Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population - A German Societal Perspective Analysis
An Ta, Felicitas Kühne, Maren Laurenz, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1

Inequitable Distribution of Global Economic Benefits from Pneumococcal Conjugate Vaccination
Fulgence Niyibitegeka, Fiona M. Russell, Mark Jit, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 767-767
Open Access | Times Cited: 1

The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US
Aleksandar Ilic, Maria J Tort, Alejandro Cané, et al.
Vaccines (2024) Vol. 12, Iss. 11, pp. 1279-1279
Open Access

Cost-Effectiveness of the Pneumococcal Vaccine in the Adult Population: A Systematic Review
Nam Xuan Vo, Huong Lai Pham, Uyen My Bui, et al.
Healthcare (2024) Vol. 12, Iss. 23, pp. 2490-2490
Open Access

Page 1

Scroll to top